Tokyo, Japan - January 26, 2022 - MBL has received approval on January 14, 2022 to manufacture and market the MEBGENTM AZF Deletion Kit, an IVD product that determines the presence or absence of microdeletions on the Y chromosome based on the PCR-rSSO (polymerase chain reaction-reverse sequence specific oligonucleotide) method.
The kit is designed to detect the presence or absence of AZF (Azoospermia Factor) deletion and the type of AZF deletion in Japanese men prior to microdissection testicular sperm extraction (micro-TESE) for male infertility. It is useful for the Y-chromosome microdeletion test.
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
Crown Bioscience and MBL Enter Joint Venture to Provide Advanced Preclinical Services for Japanes...
Crown Bioscience and MBL announce the formation of a joint venture, to further expand the provision of Crown Bioscience’s preclinical services to Japanese customers.
MBL Launches Five-test Kit for Rapid SARS-CoV-2 Antigen Detection
This product is a five-test kit version of GLINE-2019-nCoV Ag Kit (Code No. YH-G86256) which was released on February 14th as a one test kit
Launch of a New Kit for the Detection of Anti-Integrin αvβ6 Antibodies for Understanding Patholog...
Anti-integrin αvβ6 antibodies are detected in about 90% of UC patients, and the results of basic research suggest that these autoantibodies themselves may be causing the disease
MBL Donated 20,000 SARS-CoV-2 Antigen Test Kits to Ina City, Nagano Prefecture in Japan
MBL donated 20,000 their SARS-CoV-2 antigen test kits "GLINE-2019-nCoV Ag kit" to Ina City, Nagano Prefecture, where their research and production facilities are located
Acquisition of Manufacturing and Marketing Approval for SARS-CoV-2 Antigen Rapid Test and Release...
With a simple operation, the presence or absence of the SARS-CoV-2 antigen can be determined in 15 minutes